Intrinsic activity

Short description: Measure of relative response to a drug

For broader coverage of this topic, see Pharmacodynamics.

Efficacy spectrum of receptor ligands.

Intrinsic activity (IA) and maximal efficacy (Emax) refer to the relative ability of a drug-receptor complex to produce a maximum functional response. This must be distinguished from the affinity, which is a measure of the ability of the drug to bind to its molecular target, and the EC50, which is a measure of the potency of the drug and which is proportional to both efficacy and affinity. This use of the word "efficacy" was introduced by Stephenson (1956)[1] to describe the way in which agonists vary in the response they produce, even when they occupy the same number of receptors. High efficacy agonists can produce the maximal response of the receptor system while occupying a relatively low proportion of the receptors in that system. There is a distinction between efficacy and intrinsic activity.[clarification needed]

## Contents

* 1 Mechanism of efficacy
* 2 Intrinsic activity
* 3 Stevenson's efficacy
* 4 Furchgott's efficacy
* 5 References

## Mechanism of efficacy

Ligand  | Description  | % Efficacy (E)

|
|

Superagonist | Efficacy higher than the endogenous agonist  | E  | > | 100  |  |
Full agonist  | Efficacy equal to the endogenous agonist  | E  | =  | 100  |  |
Partial agonist | Efficacy less than the endogenous agonist  | 0  | < | E  | < | 100
Silent antagonist | Affinity but no efficacy  | E  | =  | 0  |  |
Inverse agonist | Inverse efficacy  | E  | < | 0  |  |

Agonists of lower efficacy are not as efficient at producing a response from the drug-bound receptor, by stabilizing the active form of the drug-bound receptor. Therefore, they may not be able to produce the same maximal response, even when they occupy the entire receptor population, as the efficiency of transformation of the inactive form of the drug-receptor complex to the active drug-receptor complex may not be high enough to evoke a maximal response. Since the observed response may be less than maximal in systems with no spare receptor reserve, some low efficacy agonists are referred to as partial agonists.[2] However, it is worth bearing in mind that these terms are relative - even partial agonists may appear as full agonists in a different system/experimental setup, as when the number of receptors increases, there may be enough drug-receptor complexes for a maximum response to be produced, even with individually low efficacy of transducing the response. There are actually relatively few true full agonists or silent antagonists; many compounds usually considered to be full agonists (such as DOI) are more accurately described as high efficacy partial agonists, as a partial agonist with efficacy over ≈80-90% is indistinguishable from a full agonist in most assays. Similarly many antagonists (such as naloxone) are in fact partial agonists or inverse agonists, but with very low efficacy (less than 10%). Compounds considered partial agonists tend to have efficacy in between this range. Another case is represented by silent agonists,[3] which are ligands that can place a receptor, typically an ion channel, into a desensitized state with little or no apparent activation of it, forming a complex that can subsequently generate currents when treated with an allosteric modulator.[4]

## Intrinsic activity

Intrinsic activity of a test agonist is defined as:

IA=maximal response to the test agonistmaximal response to full agonist[5]: 24

## Stevenson's efficacy

R. P. Stephenson (1925–2004) was a British pharmacologist.[6] Efficacy has historically been treated as a proportionality constant between the binding of the drug and the generation of the biological response.[7] Stephenson defined efficacy as:

S=ep[5]: 25

where p is the proportion of agonist-bound receptors (given by the Hill equation) and S is the stimulus to the biological system.[8] The response is generated by an unknown function f(S), which is assumed to be hyperbolic.[8] This model was arguably flawed in that it did not incorporate the equilibrium between the inactivated agonist-bound-receptor and the activated agonist-bound-receptor that is shown in the del Castillo Katz model.

## Furchgott's efficacy

Robert F. Furchgott later improved on Stephenson's model with the definition of efficacy, e, as

S=ε[R]Tot⏟e⋅p[8]

where ε is the intrinsic efficacy and [R]Tot is the total concentration of receptors.

Stevenson and Furchgott's models of efficacy have been criticised and many more have been developed. The models of efficacy are shown in Bindslev (2008).[9][10]

## References

1. ↑ "A modification of receptor theory". British Journal of Pharmacology and Chemotherapy 11 (4): 379–393. December 1956. doi:10.1111/j.1476-5381.1956.tb00006.x. PMID 13383117.
2. ↑ "In vitro pharmacology: concentration-response curves". Glaxo Wellcome pharmacology guide. http://www.pdg.cnb.uam.es/cursos/Barcelona2002/pages/Farmac/Comput_Lab/Guia_Glaxo/chap2c.html.
3. ↑ "Synthesis and evaluation of a conditionally-silent agonist for the α7 nicotinic acetylcholine receptor". Bioorganic & Medicinal Chemistry Letters 23 (14): 4145–4149. July 2013. doi:10.1016/j.bmcl.2013.05.039. PMID 23746476.
4. ↑ "Identification of α7 Nicotinic Acetylcholine Receptor Silent Agonists Based on the Spirocyclic Quinuclidine-Δ2 -Isoxazoline Scaffold: Synthesis and Electrophysiological Evaluation". ChemMedChem 12 (16): 1335–1348. August 2017. doi:10.1002/cmdc.201700162. PMID 28494140.
5. ↑ 5.0 5.1 Textbook of Receptor Pharmacology (Second ed.). CRC Press. 2009. ISBN 9781439887578. https://books.google.com/books?id=Y9bsUpefYW0C&pg=PA51.
6. ↑ "R P ('Steve') Stephenson". Pharmacology Hall of Fame. British Pharmacological Society. 2 June 2016. https://www.bps.ac.uk/about/about-pharmacology/pharmacology-hall-of-fame/articles/r-p-(-steve-)-stephenson.
7. ↑ Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). 2011. p. 46.
8. ↑ 8.0 8.1 8.2 "Kinetic Modeling Approaches to Understanding Ligand Efficacy". The Pharmacology of Functional, Biochemical, and Recombinant Receptor Systems. Berlin: Springer. 2000. p. 120. ISBN 978-3-540-66124-5.
9. ↑ "Chapter 1: Simple Agonism". Drug-Acceptor Interactions: Modeling Theoretical Tools to Test and Evaluate Experimental Equilibrium Effects. London: CRC Press. 2008. pp. 19–20. doi:10.4324/9781315159782. ISBN 978-91-977071-0-7.
10. ↑ "Drug–Acceptor Interactions–Modeling theoretical tools to test and evaluate experimental equilibrium effects (Book review)". Microbial Ecology in Health and Disease (London: Routledge) 20 (4): 213. 2017. doi:10.1080/08910600802431931. ISBN 978-1-351-66057-0.

* v
* t
* e

Pharmacology

Ligand (biochemistry)|

| Excitatory|

* Agonist
* Endogenous agonist
* Irreversible agonist
* Partial agonist
* Superagonist
* Physiological agonist

|

Inhibitory|

* Antagonist
* Competitive antagonist
* Irreversible antagonist
* Physiological antagonist
* Inverse agonist
* Enzyme inhibitor

|

* Drug
* Neurotransmitter
* Agonist-antagonist
* Pharmacophore

Pharmacodynamics|

| Activity at receptor|

* Mechanism of action
* Mode of action
* Binding
* Receptor (biochemistry)
* Desensitization (pharmacology)

|

Other effects of ligand|

* Selectivity (Binding, Functional)
* Pleiotropy (drugs)
* Non-specific effect of vaccines
* Adverse effects
* Toxicity (Neurotoxicity)

|

Analysis|

* Dose–response relationship
* Hill equation (biochemistry)
* Schild plot
* Del Castillo Katz model
* Cheng-Prussoff Equation
* Methods (Organ bath, Ligand binding assay, Patch-clamp)

|

Metrics|

* Efficacy
* Intrinsic activity
* Potency (EC50, IC50, ED50, LD50, TD50)
* Therapeutic index
* Affinity

|

Pharmacokinetics|

| Metrics|

* Loading dose
* Volume of distribution (Initial)
* Rate of infusion
* Onset of action
* Biological half-life
* Plasma protein binding
* Bioavailability

|

LADME|

* (L)ADME: (Liberation)
* Absorption
* Distribution
* Metabolism
* Excretion (Clearance)

|

* Compartment
* Bioequivalence

Related
fields|

| Neuroscience and psychology|

* Neuropsychopharmacology
* Neuropharmacology
* Psychopharmacology
* Electrophysiology

|

Medicine|

* Clinical pharmacology
* Pharmacy
* Medicinal chemistry
* Pharmacoepidemiology

|

Biochemistry and genetics|

* Pharmacoinformatics
* Pharmacogenetics
* Pharmacogenomics

|

Toxicology|

* Pharmacotoxicology
* Neurotoxicology

|

Drug discovery|

* Classical pharmacology
* Reverse pharmacology

|

* Photopharmacology
* Immunopharmacology
* Cell biology
* Physiology

Other|

* Coinduction (anaesthetics)
* Combination therapy
* Functional analog (chemistry)
* Polypharmacology
* Chemotherapy
* List of drugs
* WHO list of essential medicines

| Tolerance and resistance|

* Drug tolerance
* Tachyphylaxis
* Drug resistance
* Antibiotic resistance
* Multiple drug resistance

|

Antimicrobial pharmacology|

* Antimicrobial pharmacodynamics
* Minimum inhibitory concentration
* Bacteriostatic
* Minimum bactericidal concentration
* Bactericide

|

* v
* t
* e

Pharmacomodulation

Types|

* ♦ Enzyme: Inducer
* Inhibitor

* ♦ Ion channel: Opener
* Blocker

* ♦ Receptor: Agonist
* Partial agonist
* Antagonist
* Inverse agonist
* Positive allosteric modulator (PAM)
* Negative allosteric modulator (NAM)

* ♦ Transporter [Reuptake vs Efflux]: Enhancer (RE)
* Inhibitor (RI)
* Releaser (RA)

* ♦ Miscellaneous: Precursor
* Cofactor

Classes|

| Enzyme|

see Enzyme inhibition

|

Ion channel|

See Ion channel modulators

Receptor &
transporter|

| BA/M|

| Adrenergic|

* Adrenergic receptor agonist (α
* β (1
* 2))
* Adrenergic receptor antagonist (α (1
* 2)
* β)
* Norepinephrine reuptake inhibitor (NRI)

|

Dopaminergic|

* Dopamine receptor agonist
* Dopamine receptor antagonist
* Dopamine reuptake inhibitor (DRI)

Histaminergic|

* Histamine receptor agonist
* Histamine receptor antagonist (H1
* H2
* H3)

Serotonergic|

* Serotonin receptor agonist
* Serotonin receptor antagonist (5-HT3)
* Serotonin reuptake inhibitor (SRI)

AA|

| GABAergic|

* GABA receptor agonist
* GABA receptor antagonist
* GABA reuptake inhibitor (GRI)

|

Glutamatergic|

* Glutamate receptor agonist (AMPA)
* Glutamate receptor antagonist (NMDA)
* Glutamate reuptake inhibitor

Cholinergic|

* Acetylcholine receptor agonist (Muscarinic
* Nicotinic)
* Acetylcholine receptor antagonist (Muscarinic
* Nicotinic (Ganglionic
* Muscular))

Cannabinoidergic|

* Cannabinoid receptor agonist
* Cannabinoid receptor antagonist
* Endocannabinoid enhancer (eCBE)
* Endocannabinoid reuptake inhibitor (eCBRI)

Opioidergic|

* Opioid modulator
* Opioid receptor agonist
* Opioid receptor antagonist
* Enkephalinase inhibitor

Other|

* Adenosine reuptake inhibitor (AdoRI)
* Angiotensin II receptor antagonist
* Endothelin receptor antagonist
* NK1 receptor antagonist
* Vasopressin receptor antagonist

Miscellaneous|

* Cofactor (see Enzyme cofactors)
* Precursor (see Amino acids)

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Intrinsic activity. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Intrinsic_activity&oldid=4176963"
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template